多州建模用于治疗梅罗尼姆治疗的危急病患者的生存分析
Yaru Peng1,2, Iris K Minichmayr1,3, Han Liu1
1Department of Pharmacy, Uppsala University, Uppsala, Sweden.
CPT: pharmacometrics & systems pharmacology
|October 26, 2023
概括
对重症患者来说,优化美罗胺剂量至关重要. 达到目标抗生素度 (fT>MIC) 和考虑功能 (CLCR_CG) 通过降低死亡风险,显著影响生存率.
科学领域:
- 药学指标 (Pharmacometrics) 是一个指标.
- 临床药理学 临床药理学
- 关键护理医学 关键护理医学
背景情况:
- 危急病患者的抗生素剂量需要优化以改善结果.
- 参数生存分析是常见的,但可能会受到竞争事件的偏见.
- 药量计多态建模为分析复杂过渡提供了强大的方法.
研究的目的:
- 调查接受梅洛的危急病患者住院死亡率的预测因素.
- 开发和应用一个药量计多状态模型来捕捉患者的转变.
- 确定影响生存和治疗结果的关键因素.
主要方法:
- 开发了一种5个州的多州模型,用于577名重症患者服用梅罗.
- 分析过渡期,包括持续治疗,替代治疗,停药,出院和死亡.
- 研究的预测因素:人口统计,肌素清除率 (CLCR_CG) 和目标达到率 (fT>MIC).
主要成果:
- 在CLCR_CG下降10毫升/分钟,死亡风险增加了18%.
- 达到100%的FT>MIC显著增加了9.7%的过渡到终止治疗.
- fT>MIC的达到与改善的生存结果有关.
结论:
- 多状态建模有效预测危急病患者的死亡率.
- 功能和达到目标抗生素暴露对生存至关重要.
- 这个模型可以指导复杂的临床场景与竞争风险的生存分析.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
296
09:17Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
Published on: May 2, 2017
9.0K
相关概念视频
Comparing the Survival Analysis of Two or More Groups
201
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
201
Introduction To Survival Analysis
251
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
251
Assumptions of Survival Analysis
136
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
136
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Kaplan-Meier Approach
154
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
154
Censoring Survival Data
108
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
108
